drugset

drugset / Trial / NCT00577655

Albuterol HFA MDI in Pediatric Participants With Asthma

NCT00577655 ↗

Phase 3 Completed 103 enrolled Teva Branded Pharmaceutical Products R&D, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of this study is to evaluate the chronic-dose and efficacy of Albuterol-HFA-MDI relative to placebo in pediatric asthmatics.

Timeline

Start: 2007-08
Primary completion: 2008-07
Completion: 2008-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Salbutamol	Unknown	180 ug	Inhaled

Indications